Abeona Therapeutics Inc. (ABEO) EPS Estimated At $-0.13

March 15, 2018 - By Peter Erickson

 Abeona Therapeutics Inc. (ABEO) EPS Estimated At $ 0.13

Analysts expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report $-0.13 EPS on March, 30.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.13 EPS previously, Abeona Therapeutics Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.66% or $0.25 during the last trading session, reaching $15.35. About 577,050 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 151.02% since March 15, 2017 and is uptrending. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 36 analyst reports since December 16, 2015 according to SRatingsIntel. H.C. Wainwright maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Monday, October 9. H.C. Wainwright has “Buy” rating and $20.0 target. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, October 6 report. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by H.C. Wainwright on Wednesday, November 22. The rating was maintained by H.C. Wainwright on Thursday, August 24 with “Buy”. Cantor Fitzgerald maintained it with “Overweight” rating and $34 target in Thursday, October 12 report. The firm earned “Buy” rating on Thursday, February 8 by H.C. Wainwright. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Wednesday, April 20 by Rodman & Renshaw. On Thursday, September 14 the stock rating was initiated by RBC Capital Markets with “Buy”. On Thursday, November 2 the stock rating was maintained by RBC Capital Markets with “Buy”. The company was maintained on Tuesday, November 21 by Jefferies.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $718.00 million. The company's lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More news for Abeona Therapeutics Inc. (NASDAQ:ABEO) were recently published by: Streetinsider.com, which released: “Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: FMR LLC” on March 12, 2018. Prnewswire.com‘s article titled: “Technical Perspectives on Biotech Stocks — 22nd Century, Abeona Therapeutics …” and published on March 12, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.